Last update Sept. 19, 2016

フレカイニド酢酸塩

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Although it is concentrated in the milk, the theoretical dose ingested by the infant does not reach 6% of the therapeutic dose (Wagner 1990, McQuinn 1990), even with a maternal dose as high as 200 mg daily.

American Academy of Pediatrics: medication usually compatible with breastfeeding.

Alternatives

We do not have alternatives for フレカイニド酢酸塩 since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

フレカイニド酢酸塩 is Flecainide Acetate in Japanese.

Is written in other languages:

Group

フレカイニド酢酸塩 belongs to this group or family:

Tradenames

Main tradenames from several countries containing フレカイニド酢酸塩 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 474 daltons
Protein Binding 40 - 50 %
Tmax 3 - 4.5 hours
7 - 22 hours
M/P ratio 2.6 - 3.7 -
Theoretical Dose 0.02 - 0.23 mg/Kg/d
Relative Dose 0.3 - 7 %
Ped.Relat.Dose 0.25 - 5.8 %

References

  1. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  2. Tan HL, Lie KI. Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart J. 2001 Abstract Full text (link to original source) Full text (in our servers)
  3. Bourget P, Pons JC, Delouis C, Fermont L, Frydman R. Flecainide distribution, transplacental passage, and accumulation in the amniotic fluid during the third trimester of pregnancy. Ann Pharmacother. 1994 Abstract
  4. Wagner X, Jouglard J, Moulin M, Miller AM, Petitjean J, Pisapia A. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J. 1990 Abstract
  5. McQuinn RL, Pisani A, Wafa S, Chang SF, Miller AM, Frappell JM, Chamberlain GV, Camm AJ. Flecainide excretion in human breast milk. Clin Pharmacol Ther. 1990 Abstract

Total visits

1,303

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM